This study focuses on sarcopenia, a condition that causes loss of muscle mass and strength in elderly people. The research evaluates a new medication called BIO101 (also known as 20-hydroxyecdysone) in elderly patients who have severe sarcopenia and experience difficulty with movement. The purpose is to determine if this treatment can help prevent major mobility disability in older adults who are still able to live independently but are experiencing declining physical function.

During the study, participants will receive either BIO101 capsules at a dose of 700 milligrams per day (divided into two daily doses) or placebo capsules. The treatment will continue for up to 36 months. The medication is taken by mouth, and the study will monitor how well participants maintain their ability to move around and perform daily activities.

The research will measure several aspects of physical function, including walking speed, hand grip strength, and overall quality of life related to muscle strength. These measurements will help determine if the medication is effective in maintaining mobility and strength in elderly people with sarcopenia. The study is designed to be double-blind, which means neither the participants nor the researchers directly working with them will know who is receiving the actual medication or the placebo.